Across TCGA pan-cancer cohorts, ANXA6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANXA6 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ANXA6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ANXA6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and OV are the cancer types where ANXA6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.806	0.446	<.001	37	view →
PDAC	OS	Quartile	All	0.627	0.266	.003	10	view →
OV	DFS	Median	All	0.846	1.000	.020	8	view →
CCRCC	OS	Tertile	All	0.820	0.996	.010	6	view →
HNSC	DFS	Tertile	II,III,IV	0.887	0.986	.015	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ANXA6 tumor-vs-normal RNA expression · all ANXA6 data types